Gennao Bio is a biotech startup that specializes in the development of targeted nucleic acid therapeutics. The company's proprietary technology, GMAB, is a non-viral platform that uses a unique cell-penetrating antibody to deliver nucleic acid payloads to specific cells. This technology is primarily focused on applications in oncology and rare monogenic skeletal muscle diseases.

The GMAB technology works by binding to and delivering a wide range of nucleic acid payloads, including various types of RNA and DNA. The GMAB complexes can be delivered into both the cytoplasm and the nucleus of cells, targeting the nucleoside transporter ENT2. This transporter is highly expressed on tumor cells and skeletal muscle, allowing for precise targeting and minimizing off-target effects.

The company's business model revolves around the development and commercialization of this technology. They generate revenue through the licensing of their technology to other companies in the medical field, as well as through the development and sale of their own therapeutic products.

Gennao Bio's technology offers several advantages over traditional genetic medicines. The GMAB complexes avoid the endocytic pathway, the typical internalization mechanism for genetic medicines, which increases the bioavailability of the payload in the cell. The technology also allows for repeat dosing and dose adjustments, and is safe and well-tolerated according to clinical data. Furthermore, the manufacturing process is scalable and reproducible, and the regulatory process is well-defined.

Keywords: Biotech, Nucleic Acid Therapeutics, GMAB Technology, Oncology, Rare Monogenic Skeletal Muscle Diseases, ENT2 Targeting, Genetic Medicines, Bioavailability, Scalable Manufacturing, Regulatory Process.